Radioprotective agents for radiation therapy: future trends

Area of Science:

• Radiation oncology
• Pharmacology
• Cellular biology

Background:

• Amifostine and palifermin are the only FDA-approved radioprotective drugs for radiation therapy.
• Numerous other agents demonstrate therapeutic potential, including antioxidants and novel strategies targeting cellular responses to radiation injury.

Purpose of the Study:

• To review the current literature on radioprotector development.
• To emphasize compounds with proven or potential clinical utility in radiation therapy.

Main Methods:

• Literature review of scientific publications on radioprotective agents.
• Analysis of compounds based on their mechanisms of action (e.g., free radical scavenging, targeting cellular repair).

Main Results:

• Several classes of radioprotectors are under investigation, including superoxide dismutase mimetics, nitroxides, dietary antioxidants, cytokines/growth factors, angiotensin-converting enzyme inhibitors, and apoptotic modulators.
• These agents target either direct cellular damage or the subsequent repair pathways activated by radiation.

Conclusions:

• Radioprotector development is advancing beyond traditional antioxidants to include agents that modulate cellular responses to radiation.
• These newer strategies hold significant promise for mitigating radiation injury in patients undergoing radiation therapy.